Pipeline
We are building an exciting pipeline of multiple assets with blockbuster potential, all targeting age-related diseases.
Leramistat is an investigational first-in-class MCM which restores the body’s inherent capacity to repair and restore damaged tissue. With strong results in repair and support of hallmarks of health in studies to date, our clinical program is evaluating the potential of leramistat to repair the musculoskeletal system across several settings.
Leramistat is an investigational first-in-class MCM which restores the body’s inherent capacity to repair and restore damaged tissue. With strong results in repair and support of hallmarks of health in studies to date, our clinical program is evaluating the potential of leramistat to repair the musculoskeletal system across several settings.
Leramistat’s unique mode of action enables the prevention of damage whilst mobilising capacity to repair to restore the cross-talk between muscle and bone, offering potential as a novel treatment for primary sarcopenia of ageing.
Leramistat’s also supports adaptive repair in scarred lung tissue caused by idiopathic pulmonary fibrosis (IPF). Leramistat has been granted both FDA Fast Track and Orphan Drug Designation (ODD) to support its development for this serious condition. You can access our expanded access policy here.
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.